Skip to main content
. Author manuscript; available in PMC: 2018 Nov 7.
Published in final edited form as: Cell Metab. 2017 Oct 5;26(5):709–718.e3. doi: 10.1016/j.cmet.2017.09.005

Figure 1. FGF19 but not FGF21 has robust direct effects on hepatocytes under acute treatment conditions.

Figure 1

(A) DIO Klbfl/fl and KlbAlb littermates were i.p. injected with 1 mg/kg FGF19, FGF21 or vehicle and sacrificed 6 hr later. Cyp7a1 mRNA in liver was measured by QPCR. n = 5/group.

(B and C) DIO Klbfl/fl and KlbAlb littermates were i.p. injected with 1 mg/kg FGF19, FGF21 or vehicle and sacrificed 30 min later. (B) Phosphorylated ERK1/2 normalized to total ERK1/2 protein in liver was measured by western blot. (C) Egr1 mRNA levels in liver was measured by QPCR. n = 6/group. QPCR cycle time values are shown for the vehicle-treated Klbfl/fl group.

Data are shown as the mean ± SEM. **p < 0.01, ***p<0.001 compared to control. N.S., not significant. Significant interactions between genotype (Klbfl/fl vs. KlbAlb) and treatment (Vehicle vs. FGF19) were detected for p-ERK1/2/T-ERK/1/2 (p=0.0007) and Egr1 mRNA (p=0.004).

See also Figure S1 and Table S1.